These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 35676603)
1. Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration. Walker RJB; Look Hong NJ; Moncrieff M; van Akkooi ACJ; Jost E; Nessim C; van Houdt WJ; Stahlie EHA; Seo C; Quan ML; McKinnon JG; Wright FC; Mavros MN Ann Surg Oncol; 2022 Oct; 29(11):7010-7017. PubMed ID: 35676603 [TBL] [Abstract][Full Text] [Related]
2. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8 Egger ME; Stevenson M; Bhutiani N; Jordan AC; Scoggins CR; Philips P; Martin RC; McMasters KM J Am Coll Surg; 2019 Apr; 228(4):466-472. PubMed ID: 30660817 [TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. Isaksson K; Nielsen K; Mikiver R; Nieweg OE; Scolyer RA; Thompson JF; Ingvar C J Surg Oncol; 2018 Sep; 118(4):599-605. PubMed ID: 30196533 [TBL] [Abstract][Full Text] [Related]
5. Clinico-pathological features of patients with melanoma and positive sentinel lymph node biopsy: a single institution experience. Homolak D; Šitum M; Čupić H Acta Dermatovenerol Croat; 2015; 23(2):122-9. PubMed ID: 26228823 [TBL] [Abstract][Full Text] [Related]
6. Predictors of sentinel lymph node metastasis in very thin invasive melanomas. Kakish H; Sun J; Zheng DX; Ahmed FA; Elshami M; Loftus AW; Ocuin LM; Ammori JB; Hoehn RS; Bordeaux JS; Rothermel LD Br J Dermatol; 2023 Sep; 189(4):419-426. PubMed ID: 37290803 [TBL] [Abstract][Full Text] [Related]
7. Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database. Conic RRZ; Ko J; Damiani G; Funchain P; Knackstedt T; Vij A; Vidimos A; Gastman BR J Am Acad Dermatol; 2019 Feb; 80(2):441-447. PubMed ID: 30240775 [TBL] [Abstract][Full Text] [Related]
9. Vertical Growth Phase as a Prognostic Factor for Sentinel Lymph Node Positivity in Thin Melanomas: A Systematic Review and Meta-Analysis. Appleton SE; Fadel Z; Williams JS; Bezuhly M Plast Reconstr Surg; 2018 Jun; 141(6):1529-1540. PubMed ID: 29579032 [TBL] [Abstract][Full Text] [Related]
10. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas. Wat H; Senthilselvan A; Salopek TG J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815 [TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy in acral melanoma: A Korean single-center experience with 107 patients (2006-2018). Sohng C; Sim HB; Kim JY; Lim Y; Han MH; Lee H; Ahn BC; Huh S; Lee SJ Asia Pac J Clin Oncol; 2021 Feb; 17(1):115-122. PubMed ID: 33079454 [TBL] [Abstract][Full Text] [Related]
12. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma. Hieken TJ; Grotz TE; Comfere NI; Inselman JW; Habermann EB Melanoma Res; 2015 Apr; 25(2):157-63. PubMed ID: 25647736 [TBL] [Abstract][Full Text] [Related]
13. Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis. Kocsis A; Karsko L; Kurgyis Z; Besenyi Z; Pavics L; Dosa-Racz E; Kis E; Baltas E; Ocsai H; Varga E; Bende B; Varga A; Mohos G; Korom I; Varga J; Kemeny L; Nemeth IB; Olah J Pathol Oncol Res; 2020 Jul; 26(3):1861-1868. PubMed ID: 31792874 [TBL] [Abstract][Full Text] [Related]
14. Stratifying SLN incidence in intermediate thickness melanoma patients. Chang JM; Kosiorek HE; Dueck AC; Leong SPL; Vetto JT; White RL; Avisar E; Sondak VK; Messina JL; Zager JS; Garberoglio C; Kashani-Sabet M; Pockaj BA Am J Surg; 2018 Apr; 215(4):699-706. PubMed ID: 29502857 [TBL] [Abstract][Full Text] [Related]
15. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. Friedman C; Lyon M; Torphy RJ; Thieu D; Hosokawa P; Gonzalez R; Lewis KD; Medina TM; Rioth MJ; Robinson WA; Kounalakis N; McCarter MD; Gleisner AL J Surg Oncol; 2019 Dec; 120(7):1276-1283. PubMed ID: 31602665 [TBL] [Abstract][Full Text] [Related]
16. Validation of the Melanoma Institute of Australia's Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma. Maddineni S; Dizon MP; Muralidharan V; Young LA; Sunwoo JB; Baik FM; Swetter SM Ann Surg Oncol; 2024 Apr; 31(4):2737-2746. PubMed ID: 38216800 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. Stassen RC; Maas CCHM; van der Veldt AAM; Lo SN; Saw RPM; Varey AHR; Scolyer RA; Long GV; Thompson JF; Rutkowski P; Keilholz U; van Akkooi ACJ; Verhoef C; van Klaveren D; Grünhagen DJ Lancet Oncol; 2024 Apr; 25(4):509-517. PubMed ID: 38547894 [TBL] [Abstract][Full Text] [Related]
19. Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax. Wagner JD; Park HM; Coleman JJ; Love C; Hayes JT Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):313-21. PubMed ID: 10722003 [TBL] [Abstract][Full Text] [Related]
20. The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy. Borgognoni L; Crocetti E; Sestini S; Brandani P; Giannotti V; Gerlini G Melanoma Res; 2022 Dec; 32(6):469-476. PubMed ID: 36317389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]